| First Author | Goswami S | Year | 2023 |
| Journal | Nat Cancer | Volume | 4 |
| Issue | 10 | Pages | 1455-1473 |
| PubMed ID | 37653141 | Mgi Jnum | J:342226 |
| Mgi Id | MGI:7545739 | Doi | 10.1038/s43018-023-00620-0 |
| Citation | Goswami S, et al. (2023) Myeloid-specific KDM6B inhibition sensitizes glioblastoma to PD1 blockade. Nat Cancer 4(10):1455-1473 |
| abstractText | Glioblastoma (GBM) tumors are enriched in immune-suppressive myeloid cells and are refractory to immune checkpoint therapy (ICT). Targeting epigenetic pathways to reprogram the functional phenotype of immune-suppressive myeloid cells to overcome resistance to ICT remains unexplored. Single-cell and spatial transcriptomic analyses of human GBM tumors demonstrated high expression of an epigenetic enzyme-histone 3 lysine 27 demethylase (KDM6B)-in intratumoral immune-suppressive myeloid cell subsets. Importantly, myeloid cell-specific Kdm6b deletion enhanced proinflammatory pathways and improved survival in GBM tumor-bearing mice. Mechanistic studies showed that the absence of Kdm6b enhances antigen presentation, interferon response and phagocytosis in myeloid cells by inhibition of mediators of immune suppression including Mafb, Socs3 and Sirpa. Further, pharmacological inhibition of KDM6B mirrored the functional phenotype of Kdm6b-deleted myeloid cells and enhanced anti-PD1 efficacy. This study thus identified KDM6B as an epigenetic regulator of the functional phenotype of myeloid cell subsets and a potential therapeutic target for enhanced response to ICT. |
